Cantor Fitzgerald initiated coverage of Tvardi Therapeutics (TVRD) with an Overweight rating and $52 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVRD:
- Coinbase, Datadog, Tvardi, CF, Conagra: Trending by Analysts
- Tvardi Therapeutics initiated with an Overweight at Piper Sandler
- Tvardi Therapeutics Updates Corporate Presentation on Therapies
- Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks
- Tvardi Therapeutics files to sell 2.08M shares of common stock for holders